{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:32:03Z","timestamp":1794061923215,"version":"4.8.0"},"reference-count":118,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), subcutaneous panniculitis\u2013like T-cell lymphoma (SPTCL), and hepatosplenic T-cell lymphoma (HSTCL) are underrepresented in most registries and clinical studies. Most of the literature is obtained from small case series, single-institution retrospective studies, and subgroup analyses of the largest studies with few recent and ongoing exceptions. Although the pathogenesis and biology of these entities have yet to be fully elucidated, global efforts by the scientific community have started to shed some light on the most frequently deregulated pathways. In this review, we highlight the most pertinent clinical and pathologic features of rare subtypes of PTCL including EATL\/MEITL, SPTCL, and HSTCL. We also summarize the results of recent developments identifying potential targets for novel therapeutic strategies based on molecular studies. Finally, we highlight the underrepresentation of these rare subtypes in most clinical trials, making evidence\u2013based therapeutic decisions extremely challenging.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021788","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T20:55:36Z","timestamp":1713992136000},"page":"1898-1909","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)"],"prefix":"10.1182","volume":"144","author":[{"given":"Enrica","family":"Marchi","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Virginia Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Kalac","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2024103115205547000_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024103115205547000_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2024103115205547000_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.25674","article-title":"Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas","volume":"95","author":"Foss","year":"2020","journal-title":"Am J Hematol"},{"issue":"20","key":"2024103115205547000_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2024103115205547000_bib5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2024103115205547000_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024103115205547000_bib7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/modpathol.2015.85","article-title":"Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan","volume":"28","author":"Tomita","year":"2015","journal-title":"Mod Pathol"},{"issue":"6","key":"2024103115205547000_bib8","first-page":"806","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma: a study of four cases and review of literature","volume":"50","author":"Fei","year":"2020","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"2024103115205547000_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2010.06.006","article-title":"Enteropathy-associated T-cell lymphoma","volume":"79","author":"Ferreri","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2024103115205547000_bib10","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1080\/00365520802240222","article-title":"Incidence of enteropathy - associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands","volume":"43","author":"Verbeek","year":"2008","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"2024103115205547000_bib11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/j.gastro.2023.06.003","article-title":"Incidence and survival in patients with enteropathy-associated T-cell lymphoma: nationwide registry studies from England and Denmark","volume":"165","author":"West","year":"2023","journal-title":"Gastroenterology"},{"issue":"15","key":"2024103115205547000_bib12","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/cncr.26700","article-title":"Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008","volume":"118","author":"Sharaiha","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2024103115205547000_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cgh.2005.12.011","article-title":"Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma","volume":"4","author":"Al-Toma","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2024103115205547000_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/gutjnl-2020-322935","article-title":"Oncogenetic landscape of lymphomagenesis in coeliac disease","volume":"71","author":"Cording","year":"2022","journal-title":"Gut"},{"issue":"7","key":"2024103115205547000_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/PAS.0000000000001658","article-title":"Immunophenotypic spectrum and genomic landscape of refractory celiac disease type II","volume":"45","author":"Soderquist","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2024103115205547000_bib16","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2022.07.086","article-title":"AGA clinical practice update on management of refractory celiac disease: expert review","volume":"163","author":"Green","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"2024103115205547000_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.dld.2012.12.001","article-title":"Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study","volume":"45","author":"Malamut","year":"2013","journal-title":"Dig Liver Dis"},{"issue":"5","key":"2024103115205547000_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0002-9440(10)65736-7","article-title":"Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology","volume":"153","author":"Chott","year":"1998","journal-title":"Am J Pathol"},{"issue":"22","key":"2024103115205547000_bib19","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.3390\/cancers13225774","article-title":"Primary gastrointestinal T-cell lymphoma and indolent lymphoproliferative disorders: practical diagnostic and treatment approaches","volume":"13","author":"Nishimura","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024103115205547000_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2024103115205547000_bib21","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/PAS.0b013e318222dfcd","article-title":"Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent \u03b3\u03b4 T-cell receptor expression","volume":"35","author":"Chan","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2024103115205547000_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ajh.23213","article-title":"Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group","volume":"87","author":"Tse","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"2024103115205547000_bib23","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/leu.2013.41","article-title":"Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8\u03b1\u03b1 phenotype","volume":"27","author":"Tan","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2024103115205547000_bib24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.humpath.2013.10.038","article-title":"Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan","volume":"45","author":"Kikuma","year":"2014","journal-title":"Hum Pathol"},{"key":"2024103115205547000_bib25","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"6","key":"2024103115205547000_bib26","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0002-9440(10)64319-2","article-title":"Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions","volume":"162","author":"Mazzarella","year":"2003","journal-title":"Am J Pathol"},{"issue":"11","key":"2024103115205547000_bib27","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/leu.2016.178","article-title":"Mutations in the JAK\/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas","volume":"30","author":"Nicolae","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2024103115205547000_bib28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/leu.2016.13","article-title":"JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma","volume":"30","author":"Nairism\u00e4gi","year":"2016","journal-title":"Leukemia"},{"key":"2024103115205547000_bib29","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat Commun"},{"issue":"12","key":"2024103115205547000_bib30","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.3390\/cancers12123539","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma in Asia frequently shows SETD2 alterations","volume":"12","author":"Tomita","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024103115205547000_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"19","key":"2024103115205547000_bib32","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/bloodadvances.2020001782","article-title":"Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"4","author":"Huang","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024103115205547000_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3324\/haematol.2022.281226","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome","volume":"108","author":"Veloza","year":"2023","journal-title":"Haematologica"},{"issue":"9673","key":"2024103115205547000_bib34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(09)60254-3","article-title":"Coeliac disease","volume":"373","author":"Di Sabatino","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"2024103115205547000_bib35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024103115205547000_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004836-199806000-00026","article-title":"Enteropathy-associated T cell lymphoma with brain involvement","volume":"26","author":"Berman","year":"1998","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"2","key":"2024103115205547000_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/sjg.sjg_100_21","article-title":"Endoscopic features and clinical outcomes of enteropathy-associated T-cell lymphoma: a tertiary center retrospective study","volume":"28","author":"Chen","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"1","key":"2024103115205547000_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5009\/gnl14457","article-title":"Endoscopic findings of enteropathy-associated T-cell lymphoma type II: a case series","volume":"10","author":"Hong","year":"2016","journal-title":"Gut Liver"},{"key":"2024103115205547000_bib39","doi-asserted-by":"crossref","first-page":"100745","DOI":"10.1016\/j.ctarc.2023.100745","article-title":"Patients with enteropathy-associated T-cell lymphoma in the United States from 2000 to 2018: SEER data-base analysis","volume":"36","author":"Awad","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"2024103115205547000_bib40","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2011-10-385559","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Di Sabatino","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2024103115205547000_bib41","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2024103115205547000_bib42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI\/Cancer Research UK Phase II Study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024103115205547000_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2006.06371.x","article-title":"Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma","volume":"136","author":"Bishton","year":"2007","journal-title":"Br J Haematol"},{"key":"2024103115205547000_bib44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3332\/ecancer.2017.771","article-title":"Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges","volume":"11","author":"Gentille","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"2024103115205547000_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12029-022-00808-0","article-title":"PEG-asparaginase single-agent rescue in an advanced case of monomorphic epitheliotropic intestinal T cell lymphoma","volume":"54","author":"Barbieri","year":"2023","journal-title":"J\u00a0Gastrointest Cancer"},{"issue":"25","key":"2024103115205547000_bib46","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024103115205547000_bib47","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2022-158981","article-title":"Long-term follow-up of clinical outcome determinants and correlative biological features from the Nordic NLG-T-01 Trial","volume":"140","author":"Relander","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024103115205547000_bib48","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2024103115205547000_bib49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2021-153709","article-title":"The Eatl-001 trial: results of a phase 2 study of brentuximab vedotin and CHP followed by consolidation with high-dose therapy - autologous stem-cell transplantation (HDT-ASCT) in the frontline treatment of patients with enteropathy-associated T-cell lymphoma","volume":"138","author":"Sibon","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024103115205547000_bib50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00277-019-03791-y","article-title":"Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"98","author":"Yi","year":"2019","journal-title":"Ann Hematol"},{"issue":"suppl 5","key":"2024103115205547000_bib51","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"2024103115205547000_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.17951","article-title":"Guidelines for the management of mature T-\u00a0and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline","volume":"196","author":"Fox","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2024103115205547000_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"19","key":"2024103115205547000_bib54","first-page":"2646","article-title":"A\u00a0randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024103115205547000_bib55","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-019-0678-3","article-title":"Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"34","author":"Hu","year":"2020","journal-title":"Leukemia"},{"issue":"26","key":"2024103115205547000_bib56","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A\u00a0phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024103115205547000_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","article-title":"Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation","volume":"28","author":"Pfister","year":"2015","journal-title":"Cancer Cell"},{"issue":"23","key":"2024103115205547000_bib58","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024103115205547000_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00000478-199101000-00002","article-title":"T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome","volume":"15","author":"Gonzalez","year":"1991","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2024103115205547000_bib60","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2024103115205547000_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ajcp\/103.5.543","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version","volume":"103","author":"Chan","year":"1995","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2024103115205547000_bib62","first-page":"617","article-title":"Expression of the alpha\/beta and gamma\/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma\/delta T-cell lymphomas","volume":"137","author":"Gaulard","year":"1990","journal-title":"Am J Pathol"},{"issue":"9","key":"2024103115205547000_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clml.2023.05.012","article-title":"SOHO state of the art updates and next questions | challenging cases in rare T-cell lymphomas","volume":"23","author":"Bhansali","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2024103115205547000_bib64","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamadermatol.2022.3347","article-title":"Clinical and pathological characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma and related adipotropic lymphoproliferative disorders","volume":"158","author":"Guitart","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"21","key":"2024103115205547000_bib65","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2024103115205547000_bib66","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2024103115205547000_bib67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2230.2003.01374.x","article-title":"Characteristics of cutaneous lymphomas in Korea","volume":"28","author":"Lee","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2024103115205547000_bib68","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2024103115205547000_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/DAD.0b013e31826b4b1a","article-title":"CCL5 expression in panniculitic T-cell dyscrasias and its potential role in adipocyte tropism","volume":"35","author":"Magro","year":"2013","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"2024103115205547000_bib70","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1684\/ejd.2017.3016","article-title":"CCR4 and CCR5 expression in a case of subcutaneous panniculitis-like T-cell lymphoma","volume":"27","author":"Kitayama","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"11","key":"2024103115205547000_bib71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/cup.13025","article-title":"Immunohistochemistry reveals an increased proportion of MYC-positive cells in subcutaneous panniculitis-like T-cell lymphoma compared with lupus panniculitis","volume":"44","author":"Fernandez-Pol","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"issue":"6","key":"2024103115205547000_bib72","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/PAS.0000000000000596","article-title":"Useful parameters for distinguishing subcutaneous panniculitis-like T-cell lymphoma from lupus erythematosus panniculitis","volume":"40","author":"LeBlanc","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2024103115205547000_bib73","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/PAS.0000000000002133","article-title":"IRF8 in conjunction with CD123 and CD20 to distinguish lupus erythematosus panniculitis from subcutaneous panniculitis-like T-cell lymphoma","volume":"47","author":"Wong","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2024103115205547000_bib74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bjh.14611","article-title":"Recurrent mutations in epigenetic modifiers and the PI3K\/AKT\/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"2024103115205547000_bib75","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"2024103115205547000_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"issue":"20","key":"2024103115205547000_bib77","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/bloodadvances.2021004562","article-title":"Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations","volume":"5","author":"Koh","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2024103115205547000_bib78","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.05.1243","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients","volume":"79","author":"L\u00f3pez-Lerma","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"2024103115205547000_bib79","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/DAD.0000000000000486","article-title":"Kikuchi-Fujimoto disease associated with subcutaneous panniculitis-like T-cell lymphoma","volume":"38","author":"Notaro","year":"2016","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"2024103115205547000_bib80","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1007\/s10238-023-01210-1","article-title":"Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature","volume":"23","author":"Ou","year":"2023","journal-title":"Clin Exp Med"},{"issue":"6","key":"2024103115205547000_bib81","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024103115205547000_bib82","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"2024103115205547000_bib83","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024103115205547000_bib84","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"L\u00e9vy","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl","key":"2024103115205547000_bib85","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/01.HS9.0000847552.42271.7c","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 Primo Trial: updated expansion phase analysis","volume":"6","author":"Zinzani","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2024103115205547000_bib86","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.18817","article-title":"Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children","volume":"202","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2024103115205547000_bib87","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.leu.2401784","article-title":"Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990","volume":"14","author":"Weidmann","year":"2000","journal-title":"Leukemia"},{"issue":"5","key":"2024103115205547000_bib88","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/PAS.0000000000000614","article-title":"Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases","volume":"40","author":"Yabe","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2024103115205547000_bib89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/gcc.2870120302","article-title":"Consistent presence of isochromosome 7q in hepatosplenic T gamma\/delta lymphoma: a new cytogenetic-clinicopathologic entity","volume":"12","author":"Wang","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"issue":"24","key":"2024103115205547000_bib90","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024103115205547000_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"},{"issue":"11","key":"2024103115205547000_bib92","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas","volume":"28","author":"Nicolae","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2024103115205547000_bib93","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF-\u03b1 inhibitor therapy: expanding the groups at risk","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"2024103115205547000_bib94","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024103115205547000_bib95","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.2147\/IJGM.S335464","article-title":"Survival analysis of hepatosplenic T cell lymphoma: a population-based study using SEER","volume":"14","author":"Li","year":"2021","journal-title":"Int J Gen Med"},{"issue":"6","key":"2024103115205547000_bib96","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"issue":"13","key":"2024103115205547000_bib97","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2024103115205547000_bib98","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.10.007","article-title":"Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma","volume":"20","author":"Klebaner","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2024103115205547000_bib99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024103115205547000_bib100","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"7","key":"2024103115205547000_bib101","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1245\/s10434-009-0470-0","article-title":"Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia","volume":"16","author":"Gumbs","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2024103115205547000_bib102","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2024103115205547000_bib103","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2006.00646.x","article-title":"A\u00a0case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab","volume":"76","author":"Mittal","year":"2006","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024103115205547000_bib104","first-page":"Ecr14","article-title":"Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas","volume":"90","author":"Corazzelli","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"2024103115205547000_bib105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdn119","article-title":"Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine","volume":"19","author":"Jaeger","year":"2008","journal-title":"Ann Oncol"},{"issue":"10168","key":"2024103115205547000_bib106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2024103115205547000_bib107","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024103115205547000_bib108","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024103115205547000_bib109","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O'Connor","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024103115205547000_bib110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral t-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"2024103115205547000_bib111","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1200\/JCO.2022.40.16_suppl.7563","article-title":"A phase I\/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024103115205547000_bib112","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"2022. The cobalt-lym study of ctx130: a phase 1 dose escalation study of cd70-targeted allogeneic crispr-cas9\u2013engineered car t cells in patients with relapsed\/refractory (r\/r) t-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"issue":"13","key":"2024103115205547000_bib113","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"suppl1","key":"2024103115205547000_bib114","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in human study of AUTO4, a TRBC1-targeting CAR T-Cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"},{"issue":"suppl","key":"2024103115205547000_bib115","doi-asserted-by":"crossref","first-page":"e6843062","DOI":"10.1097\/01.HS9.0000971464.68430.62","article-title":"AFM13 in patients with r\/r peripheral T cell lymphoma (ptcl): a post-hoc subgroup analysis from the redirect study","volume":"7","author":"Kim","year":"2023","journal-title":"HemaSphere"},{"issue":"6","key":"2024103115205547000_bib116","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2024103115205547000_bib117","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"2024103115205547000_bib118","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1898\/2311671\/blood_bld-2023-021788-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1898\/2311671\/blood_bld-2023-021788-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:21:27Z","timestamp":1730388087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/18\/1898\/515890\/Current-and-upcoming-treatment-approaches-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":118,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,10,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021788","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}